Roger Song
Stock Analyst at Jefferies
(0.94)
# 3,707
Out of 4,868 analysts
46
Total ratings
31.58%
Success rate
-18.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERV Verve Therapeutics | Downgrades: Hold | $28 → $11 | $11.12 | -1.08% | 1 | Jun 18, 2025 | |
| CVAC CureVac | Downgrades: Hold | $7 → $5 | $5.49 | -8.93% | 1 | Jun 13, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $40 → $45 | $27.93 | +61.12% | 2 | Apr 29, 2025 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $15 → $30 | $8.61 | +248.43% | 11 | Apr 11, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Buy | $6 | $3.56 | +68.54% | 1 | Apr 1, 2025 | |
| SANA Sana Biotechnology | Initiates: Buy | $7 | $2.76 | +153.62% | 1 | Mar 14, 2025 | |
| KRYS Krystal Biotech | Initiates: Buy | $245 | $131.76 | +85.94% | 1 | Mar 5, 2025 | |
| WVE Wave Life Sciences | Initiates: Buy | $26 | $6.90 | +276.81% | 1 | Feb 25, 2025 | |
| IGMS IGM Biosciences | Downgrades: Hold | $48 → $2 | $1.17 | +70.94% | 2 | Jan 10, 2025 | |
| BIOA BioAge Labs | Downgrades: Hold | $42 → $7 | $4.38 | +60.00% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $9.49 | +100.21% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $6.06 | +362.05% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $1.42 | +392.96% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $50.15 | +77.47% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $6.30 | +296.83% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $11.62 | +252.84% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $9.39 | +272.74% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.17 | +74.08% | 1 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $33.41 | +286.11% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $2.11 | +279.15% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $75.53 | +28.43% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $72 | $16.83 | +327.81% | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $26.28 | +318.57% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $6.78 | +416.22% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.86 | +945.17% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.93 | +103.56% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $0.79 | +2,545.50% | 1 | Sep 2, 2020 |
Verve Therapeutics
Jun 18, 2025
Downgrades: Hold
Price Target: $28 → $11
Current: $11.12
Upside: -1.08%
CureVac
Jun 13, 2025
Downgrades: Hold
Price Target: $7 → $5
Current: $5.49
Upside: -8.93%
Kiniksa Pharmaceuticals International,
Apr 29, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $27.93
Upside: +61.12%
Nektar Therapeutics
Apr 11, 2025
Upgrades: Buy
Price Target: $15 → $30
Current: $8.61
Upside: +248.43%
Akebia Therapeutics
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $3.56
Upside: +68.54%
Sana Biotechnology
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $2.76
Upside: +153.62%
Krystal Biotech
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $131.76
Upside: +85.94%
Wave Life Sciences
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $6.90
Upside: +276.81%
IGM Biosciences
Jan 10, 2025
Downgrades: Hold
Price Target: $48 → $2
Current: $1.17
Upside: +70.94%
BioAge Labs
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $4.38
Upside: +60.00%
Dec 4, 2024
Maintains: Buy
Price Target: $16 → $19
Current: $9.49
Upside: +100.21%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $6.06
Upside: +362.05%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $1.42
Upside: +392.96%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $50.15
Upside: +77.47%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $6.30
Upside: +296.83%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $11.62
Upside: +252.84%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $9.39
Upside: +272.74%
Sep 5, 2024
Initiates: Buy
Price Target: $9
Current: $5.17
Upside: +74.08%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $33.41
Upside: +286.11%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $2.11
Upside: +279.15%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $75.53
Upside: +28.43%
Mar 20, 2024
Maintains: Buy
Price Target: $41 → $72
Current: $16.83
Upside: +327.81%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $26.28
Upside: +318.57%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $6.78
Upside: +416.22%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $0.86
Upside: +945.17%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $3.93
Upside: +103.56%
Sep 2, 2020
Initiates: Buy
Price Target: $21
Current: $0.79
Upside: +2,545.50%